Physician profile
Muhammad Muslim
NPI 1861571218
$6,917.21
in general payments reported to CMS, 2019-2025
49 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.85 · 2022: $21.56 · 2024: $3,917 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,071 · Long Term Medical Supply Or Device Loan: $598 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,071.08 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Education | $200.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,110.94 | 2024-2025 | |
| Pfizer INC. | $497.42 | 2024-2025 | |
| Eisai INC. | $378.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.73 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $310.89 | 2024-2025 | Pomalyst, Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $296.30 | 2022-2025 | Opdivo, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $295.03 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $293.40 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $278.26 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $262.30 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $257.32 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $229.12 | 2024-2025 | Jakafi, Monjuvi |
| Sobi, INC | $195.50 | 2024-2025 | |
| Abbvie INC. | $180.20 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.81 | 2024-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $125.83 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Karyopharm Therapeutics INC. | $121.39 | 2024-2025 | Xpovio |
| Astellas Pharma US INC | $111.05 | 2024-2025 | Xtandi, Vyloy, Padcev |
| Genzyme Corporation | $107.10 | 2024-2025 | |
| Puma Biotechnology, INC. | $95.37 | 2024-2025 | |
| Gilead Sciences, INC. | $92.41 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $83.27 | 2024 | Verzenio, Jaypirca |
| Blueprint Medicines Corporation | $70.73 | 2024-2025 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $70.00 | 2024 | Provenge |
| Beone Medicines USA, INC. | $67.33 | 2025 | Brukinsa |
| Springworks Therapeutics, INC. | $66.66 | 2024-2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $64.02 | 2024-2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $62.76 | 2025 | |
| Genentech USA, INC. | $57.89 | 2024-2025 | Tecentriq, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.25 | 2024-2025 | Gilotrif |
| Verity Pharmaceuticals INC. | $56.38 | 2025 | Trelstar |
| Exelixis INC. | $54.54 | 2024-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $52.04 | 2024-2025 | |
| Tempus Ai, INC | $46.23 | 2024 | |
| Taiho Oncology, INC. | $43.22 | 2024-2025 | |
| Emmaus Medical, INC. | $34.27 | 2024 | Endari |
| Acrotech Biopharma INC. | $31.04 | 2021-2024 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $29.48 | 2024 | Libtayo |
| Legend Biotech USA INC. | $25.39 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $24.25 | 2024 | Sylvant |
| Servier Pharmaceuticals LLC | $23.58 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.04 | 2024 | Somatuline Depot, Onivyde |
| Fennec Pharmaceuticals, INC. | $18.05 | 2025 | Fyarro |
| Amgen INC. | $16.93 | 2025 | Kyprolis, Blincyto |
| Sumitomo Pharma America, INC. | $16.75 | 2024 | Orgovyx |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $16.03 | 2025 | Vivimusta, Danziten |
| Rigel Pharmaceuticals, INC. | $15.40 | 2024 | Rezlidhia, Tavalisse |
| Iovance Biotherapeutics, INC. | $6.92 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Muslim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.